Prophylaxis of deep vein thrombosis in high risk patients undergoing total hip replacement with low molecular weight heparin plus dihydroergotamine

Arzneimittelforschung. 1987 Jul;37(7):839-43.

Abstract

In 160 high risk patients with total hip replacement the antithrombotic efficacy and tolerance of a single daily injection of 1500 aPTT-U (aPTT = activated partial thromboplastin time) low molecular weight heparin plus 0.5 mg dihydroergotamine (HNMD; Embolex NM) was compared with a twice daily application of 5000 IU of the heparin-dihydroergotamine combination Heparin-Dihydergot in a double-blind study. Deep vein thrombosis measured by means of the radiofibrinogen uptake test occurred in 20.5% of patients in both groups. In addition, intra- and postoperative blood loss and the development of hematoma were similar in both groups. Thus, on account of the "once-daily" application HNMD offers some substantial advantages: The stress of the patient in the postoperative convalescence phase can be appreciably lowered and thereby the nursing staff are spared a great deal of work.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Clinical Trials as Topic
  • Dihydroergotamine / adverse effects
  • Dihydroergotamine / therapeutic use*
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Heparin, Low-Molecular-Weight / adverse effects
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Hip Prosthesis*
  • Humans
  • Male
  • Postoperative Complications / etiology
  • Postoperative Complications / prevention & control
  • Random Allocation
  • Risk Factors
  • Thrombophlebitis / prevention & control*

Substances

  • Heparin, Low-Molecular-Weight
  • Dihydroergotamine